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Summary  Brucellosis  is  a  zoonotic  disease  caused  by  Brucella  spp.  that  is  transmit-
ted  to  humans  by  the  ingestion  of  unpasteurized  milk  and  other  dairy  products  from
infected  animals  or  through  close  contact  with  secretions.  Crimean-Congo  hemor-
rhagic  fever  (CCHF)  is  a  tick-borne  disease  caused  by  a  virus  that  is  transmitted  to
humans  by  ixoid  tick  bites,  contact  with  blood  and  tissue  of  infected  animals  or
contact  with  infected  humans.  The  symptoms  of  brucellosis  are  non-speciﬁc;  it  can
mimic  other  diseases.  In  this  paper,  we  present  a  case  of  brucellosis  that  was  ini-
tially  evaluated  as  CCHF.  We  emphasize  that  brucellosis  should  be  considered  in  the
differential  diagnosis  of  CCHF,  especially  in  endemic  countries.
©  2014  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
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Brucellosis  is  a  common  bacterial  zoonotic  infec-
tion in  Turkey.  The  disease  can  involve  many
systems, including  the  reticuloendothelial  system,
musculoskeletal  system,  gastrointestinal  system,
lymphoreticuler  system  and  central  nervous  sys-
tem, so  it  can  present  with  a  wide  clinical
polymorphism  [1].  We  report  a  case  of  brucellosis
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f CCHF.
ase Report
 previously  healthy  11-year-old  girl  was  referred
o our  hospital  with  complaints  of  fever,  fatigue,
bdominal pain  and  bleeding  and  a pre-diagnosis
f CCHF.  She  was  living  in  a village,  and  her  fam-
ly was  engaged  in  animal  husbandry.  She  had
 history  of  ingestion  of  unpasteurized  milk  and
nces. Published by Elsevier Limited. All rights reserved.
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trucellosis  mimicking  Crimean-Congo  hemorrhagic  
ilk  products.  She  had  no  history  of  tickbites.
er vital  signs  were  normal,  except  for  a low
rade fever.  The  physical  examination  revealed
pistaxis, petechial/ecchymotic  rashes  and  mild-
o-moderate  mucosal  bleeding  in  her  mouth.  The
est of  the  physical  examination  ﬁndings  were  unre-
arkable.  Initial  whole  blood  count  revealed  a
emoglobin  level  of  10.5  g/dL,  white  blood  count
f 6400  mm—3,  and  platelet  count  of  5000  mm—3.
he prothrombin  time  was  15  s  (11—13.2  s),  INR
as 1.07,  and  activated  partial  thromboplastin  time
as 30.3  s  (20—31  s).  Biochemical  examinations
ere alanine  aminotransferase  289  U/L  (5—40  U/L),
spartate  aminotransferase  297  U/L  (8—33  U/L),
actate  dehydrogenase  412  U/L  (110—295  U/L),
nd creatine  kinase  70  U/L  (<247  U/L).  Abdominal
ltrasonography  revealed  splenomegaly.  Ebstein-
arr virus  VCA  IgM,  leishmania  IFAT/dipstick  and
nzyme-linked  immunoassay  (ELISA)  tests  were
egative.  The  patient  was  given  a  preliminary  diag-
osis of  CCHF  because  she  was  living  in  the  endemic
egion of  Turkey  and  her  complaints  and  laboratory
ndings were  compatible  with  the  disease.  There-
ore,  a  serum  sample  from  the  patient  was  sent
o the  Public  Health  Institution  of  Turkey  for  CCHF
LISA and  polymerase  chain  reaction  (PCR)  tests.
ntravenous  ceftriaxone  and  ribavirin  were  adminis-
ered empirically,  and  intravenous  immunoglobulin
IVIg) and  platelet  suspension  were  given  because
f bleeding.  Bone  marrow  examination  revealed
one marrow  suppression.  Blood  and  bone  mar-
ow bacterial  cultures  were  sterile.  CCHF  PCR  and
LISA tests  were  negative.  Brucella  IgM  and  IgG
ere positive  with  enzyme  immunoassay  (EIA).  Bru-
ella tube  agglutination  with  Coombs  test  was
ositive  at  a  titer  of  1/320.  Ribavirin  treatment
as halted  on  the  fourth  day,  and  doxycycline
lus rifampicin  combination  therapy  was  initiated,
hich  caused  the  patient’s  thrombocyte  count  and
emoglobin  level  to  increase  and  become  nor-
al (230,000  mm—3, 13.5  g/dL)  by  the  16th  day  of
reatment.  She  fully  recovered  at  the  end  of  the
ix-week period  of  the  treatment  regimen.
iscussion
CHF  is a  tick-borne  disease  that  is  caused  by  a
irus and  is  a  member  of  the  genus  Nairovirus  of
he family  Bunyaviridae.  CCHF  was  ﬁrst  observed
n Turkey  in  2002,  and  from  2002  to  2010,  5321
atients were  reported  [2]. CCHF  remains  a  sea-
onal problem  in  the  Mid-Eastern  Anatolia  region
f Turkey  to  date.  The  main  transmission  route  is
ick contact,  and  the  primary  route  of  transmission
n cases  with  no  history  of  tick  contact  is  close
t
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ontact  with  animals.  The  patient  had  no  his-
ory of  tick  contact,  but  her  family  was  working
n animal  husbandry.  The  hemorrhagic  phase  of
CHF is  characterized  by  petechiae  and  ecchy-
oses, hematuria,  epistaxis,  and  bleeding  from  any
ucosal surface  [3]. Thrombocytopenia,  leukope-
ia and  elevated  transaminase  levels  are  the  most
ommon  laboratory  ﬁndings  reported  in  patients
ith CCHF  [4]. Because  of  the  presence  of com-
atible epidemiological,  clinical  and  laboratory
ndings of  CCHF,  the  patient  was  isolated  and
arly ribavirin  treatment  was  initiated  as  recom-
ended  [5].  The  patient  presented  with  bleeding
ymptoms associated  with  severe  thrombocyto-
enia, and  IVIg  treatment  was  given  as  an  urgent
reatment because  of  the  diagnosis  of  immune
hrombocytopenia.  When  CCHF,  PCR  and  ELISA  tests
ame back  negative,  bone  marrow  aspiration  was
onducted  and  revealed  bone  marrow  suppression
Table  1).
It was  reported  that  the  differential  diagnosis
f CCHF  should  include  rickettsiosis,  leptospirosis,
orreliosis, brucellosis,  leishmaniasis,  meningococ-
emia, Hantavirus  hemorrhagic  fever  and  malaria
3,5]. Thereafter  brucellosis  was  diagnosed  by
ositive  serological  tests,  and  anti-brucellosis
reatment  was  initiated.  Under  the  anti-brucellosis
reatment, a  rapid  increase  in  thrombocyte  count
as detected.  Although  our  patient  had  been
reated with  IVIg  before  the  diagnosis  of  brucel-
osis, we  suggested  that  thrombocytopenia  induced
irectly  by  infection  should  be  treated  by  treating
he infectious  agent  itself.
Brucellosis  is  a zoonotic  disease  caused  by  Gram-
egative  bacteria,  Brucella  spp.  Consumption  of
aw milk  and  milk  products  and  contact  with
nfected animals  or  their  waste  materials  are  the
ain routes  of  infection  [6].  Our  patient  had  a
istory of  ingestion  of  raw  cheese.  Brucella  infec-
ion spreads  hematogenously  and  mainly  involves
he reticuloendothelial  system.  A  variety  of  non-
peciﬁc  hematological  abnormalities,  such  as  mild
nemia and  leucopenia,  have  been  frequently
ssociated with  acute  brucellosis,  but  thrombo-
ytopenia is  less  frequently  reported  in  patients
7,8]. Thrombocytopenia  is  usually  moderate  and
s attributed  to  bone  marrow  suppression  or  hyper-
plenism.  In  contrast  to  this,  thrombocytopenia  of
he current  case  was  severe  and  associated  with
leeding.  There  were  no  laboratory  or  bone  mar-
ow results  of  DIC  or  hemophagocytosis.  Although
here are  several  reports  of  brucellosis-induced
hrombocytopenia,  severe  thrombocytopenia  asso-
iated with  purpura,  mucosal  bleeding  and  epistaxis
s the  initial  manifestation  of  brucellosis  like
ur patient  is  a  rare  phenomenon  [9].  Isolated
304  O.  Metin  et  al.
Table  1  Laboratory  investigations  during  the  hospitalization.
Day  of  hospi-
talization
Hemoglobin
level  (g/dL)
Leukocyte
count  (/mm3)
Platelet  count
(/mm3)
ALT  (U/L)  AST  (U/L)
1  10.5  6400  5000  289  289
2  10  3700  10,000  193  177
3  9.3  3900  42,000  —  —
5  9.8  2800  34,000  110  77
9  10.6 3600  80,000  —  —
16  13.5 6300  230,000  59  44
e.
RALT, alanine aminotransferase; AST, aspartate aminotransferas
thrombocytopenia  and  clinically  detectable  bleed-
ing were  reported  in  8%  and  1%  of  patients,
respectively,  in  a  study  from  Turkey  [10].
This case  report  describes  a  patient  with  severe
thrombocytopenia  who  was  diagnosed  with  bru-
cellosis.  The  rare  presentation  of  the  disease
may cause  it  to  be  confused  with  CCHF,  espe-
cially in  the  epidemic  season.  Both  of  these
diseases are  endemic  in  Turkey.  Brucellosis  should
be kept  in  mind  in  the  differential  diagnosis  of
severe  thrombocytopenia  and  CCHF.  In  the  case  of
thrombocytopenia,  an  excellent  response  can  be
achieved with  the  speciﬁc  treatment  of  brucellosis.
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